Numis at a glance

Latest Transactions
Clinigen
£1.3bn
Recommended £1.3bn cash offer for Clinigen by Triton
April 2022
Randall & Quilter
£480m
Recommended cash offer by Brickell PC for a deal value of £480m plus $100m of equity
April 2022

Clinigen Group - £1.3bn buy-out

Numis is delighted to have acted as joint financial adviser and broker to Clinigen Group plc on its £1.3bn buy-out by Triton Investment Management.

Internal banner
We are delighted to have played a prominent role in supporting Clinigen on its £1.26bn buy-out by Triton, a leading European private equity firm, for which the scheme of arrangement has now become effective.

Clinigen is a global pharmaceutical services and products company focused on providing ethical access to medicines with a mission to deliver the right medicine to the right patient at the right time. The business operates from sites in North America, Europe, Africa and Asia Pacific. 

Numis is proud of our long-standing relationship with Clinigen. It is a business we first IPO’d in 2012 and have supported the company on its organic and inorganic growth strategy in the years since.

The offer price of 925p per share, which was the seventh of seven unsolicited proposals from Triton, represented a 48% premium to the (ex-div) closing price and a 50% premium to the six-month volume weighted average (ex-div) price at close of business on 1 December 2021, the last business day before the start of the offer period.

The Numis team provided key input on value and tactics, as well as process management and shareholder insight.

“It is fantastic to see Numis once again providing a long-term client with quality, independent financial and tactical advice and robust shareholder insight. The successful execution of yet another substantial public to private transaction reinforces Numis’ excellent credentials as a leading financial adviser on UK public offers.”

Stuart Ord Managing Director, M&A Advisory

This transaction is a great outcome for Clinigen and we are very proud of the team involved.

For further information, please reach out to your Numis representative. 

Investment Banking

Equities